Why Did OTLK Stock Crash In Pre-Market Today?
Outlook Therapeutics is looking to sell about 55.6 million common shares, accompanied by warrants, at a 10% discount over the stock’s closing price on Wednesday. Outlook plans to use the funds, alongside its existing cash, to support the U.S. commercial launch of its eye drug Lytenava. Lytenava received U.S. Food and Drug Administration approval for … Read more